Agilent Technologies — Merger or Acquisition (July 2024)

4 slides from Agilent Technologies's merger presentation, Jul 22, 2024

Slide 1: Agilent to acquire BIOVECTRA: Investor Highlights
Agilent to acquire BIOVECTRA Investor Highlights July 22, 2024
Slide 2: Safe Harbor Statement and Footnotes
Safe Harbor Statement and Footnotes These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, ca
Slide 3: Strategic Rationale
Strategic Rationale Expanding our CDMO customer offering in high-growth modalities • Enhances depth of relationships with key pharma customers focused on biologics • Expands presence in faster growing segments of the market – GLP-1s, ADCs, HPAPIs • Vertically expands technical capabilities and comme
Slide 4: Transaction highlights
Transaction highlights Purchase Price $925M, financed with a mix of debt and cash on hand $113M in 2023 revenue, on track for $130M+ in 2024 Revenue Expect double-digit growth in 2024 and for the next 5 years Currently high-teens operating margins, increased capacity Margins utilization expected to